Table.
Case 1 | Case 2 | Case 3 | ||||
---|---|---|---|---|---|---|
Age | 10y7m | 13y11m | 10y8m | |||
Sex | Female | Female | Female | |||
Body height (m) | 1.42 | 1.51 | 1.37 | |||
Body weight (kg) | 48.9 | 38.0 | 30.9 | |||
History of anti-HCV therapy | No | No | No | |||
Leukocyte count (/mm3) | 7,480 | 5,260 | 8,720 | |||
Hemoglobin (g/dL) | 13.9 | 13.1 | 13.8 | |||
Platelet count (×104/µL) | 24.6 | 25.4 | 35.9 | |||
Prothrombin activity (%) | 98 | 97 | 97 | |||
Total bilirubin (mg/dL) | 0.7 | 1.1 | 0.5 | |||
Aspartate aminotransferase (U/L) | 38 | 18 | 33 | |||
Alanine aminotransferase (U/L) | 52 | 20 | 19 | |||
Albumin (g/dL) | 4.2 | 4.3 | 4.7 | |||
Alpha-fetoprotein (ng/mL) | 0.9 | 2.2 | 1.6 | |||
FIB4 index | 0.22 | 0.21 | 0.22 | |||
Fibroscan (kPa) | 5.3 | 3.7 | 3.0 | |||
HCV genotype in children | 1b | 1b | 1b | |||
HCV genotype in mothers | 1b | 1b | 1b | |||
HCV RNA (log IU/mL) | 5.2 | 4.9 | 5.2 | |||
NS3-D168 | Wild | Wild | Wild | |||
NS5A-L31 | Wild | Mix (L>>I/V) | Wild | |||
NS5A-Y93 | Wild | Wild | Wild | |||
Regimens of DAAs | OBV+PTV/r | OBV+PTV/r | GLE+PIB | |||
Doses of DAAs | OBV 25 mg | OBV 25 mg | GLE 300 mg | |||
PTV 150 mg | PTV 150 mg | PIB 120 mg | ||||
r 100 mg | r 100 mg |
OBV+PTV/r: ombitasvir+paritaprevir/ritonavir, GLE+PIB: glecaprevir+pibrentasvir